Clinical Trials · NCT03861052
A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 636
- Start date
- May 2019
- Locations
- 46 sites, Japan
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c)